Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action  by Lucas, Guillaume et al.
Neuron
ArticleSerotonin4 (5-HT4) Receptor Agonists Are Putative
Antidepressants with a Rapid Onset of Action
Guillaume Lucas,1,3,* Vladimir V. Rymar,2 Jenny Du,3 Ouissame Mnie-Filali,4 Christina Bisgaard,5 Stella Manta,1
Laura Lambas-Senas,4 Ove Wiborg,5,6 Nasser Haddjeri,4 Graciela Pin˜eyro,3 Abbas F. Sadikot,2
and Guy Debonnel1,7
1Universite´ McGill, De´partement de Psychiatrie, Baˆtiment de Recherche et de Formation, Bureau 207, 1033 Avenue des Pins
Ouest, Montre´al, QC, H3A 1A1 Canada
2Universite´ McGill, De´partement de Neurologie et Neurochirurgie, Institut Neurologique de Montre´al, Montre´al, QC,
H3A 2B4 Canada
3Centre de Recherche Fernand Se´guin, Universite´ de Montre´al, Montre´al, QC, H1N 3V2 Canada
4Laboratoire de Neuropharmacologie et Neurochimie, Universite´ Claude Bernard Lyon 1, Lyon, France
5Centre for Basic Psychiatric Research, Aarhus Psychiatric University Hospital, Aarhus, Denmark
6OWn Research Aps, Science Park Skejby, Brendstrupsgaardsvej 102, Aarhus, Denmark
7Guy Debonnel passed away on November 4, 2006, and this article is dedicated to his memory.
*Correspondence: guillaume.lucas@gmail.com
DOI 10.1016/j.neuron.2007.07.041SUMMARY
Current antidepressants are clinically effective
only after several weeks of administration.
Here, we show that serotonin4 (5-HT4) agonists
reduce immobility in the forced swimming test,
displaying an antidepressant potential. More-
over, a 3 day regimen with such compounds
modifies rat brain parameters considered to
be key markers of antidepressant action, but
that are observed only after 2–3 week treat-
ments with classical molecules: desensitization
of 5-HT1A autoreceptors, increased tonus on
hippocampal postsynaptic 5-HT1A receptors,
and enhanced phosphorylation of the CREB
protein and neurogenesis in the hippocampus.
In contrast, a 3 day treatment with the SSRI cit-
alopram remains devoid of any effect on these
parameters. Finally, a 3 day regimen with the
5-HT4 agonist RS 67333 was sufficient to
reduce both the hyperlocomotion induced by
olfactory bulbectomy and the diminution of
sucrose intake consecutive to a chronic mild
stress. These findings point out 5-HT4 receptor
agonists as a putative class of antidepressants
with a rapid onset of action.
INTRODUCTION
Considerable work has been devoted to the study of the
mechanisms of antidepressant (AD) action, and it is now
widely accepted that an increased central serotonergic
(5-HT) neurotransmission constitutes a key therapeutic
factor of such compounds (Blier and de Montigny, 1994,
1999). This hypothesis has been strengthened by the712 Neuron 55, 712–725, September 6, 2007 ª2007 Elsevier Incsuccessful use of selective serotonin reuptake inhibitors
(SSRIs), the most commonly prescribed AD. Unfortunately
for patients and clinicians, the mood improvement starts
only after 3–6 weeks of AD treatment. Similarly, in animal
behavioral models of depression, a period of 2–3 weeks
of continuous administration is required to obtain an ‘‘an-
tidepressant-like’’ effect. In keeping with these observa-
tions, a number of typical changes occur in the central
5-HT transmission of AD-administered rodents within the
same time frame. These modifications include the desen-
sitization of presynaptic 5-HT1A autoreceptors (Blier and
de Montigny, 1994, 1999; Mongeau et al., 1997; Blier,
2001; Artigas et al., 2002) and a strong increase of the
inhibitory tonus mediated by postsynaptic 5-HT1A recep-
tors, particularly within the hippocampus (Haddjeri et al.,
1998; Besson et al., 2000; Blier and Ward, 2003). Long-
term treatments with ADs also activate neurogenesis in
the hippocampus (Malberg et al., 2000; Nakagawa et al.,
2002a; Santarelli et al., 2003). This requires the presence
of 5-HT1A receptors, and recent work indicates that acti-
vation of adult hippocampal neurogenesis may help medi-
ate the beneficial action of ADs (Santarelli et al., 2003;
Castre´n, 2004). Several studies have suggested that
AD-induced neurogenesis is related to an elevation of
the cAMP response element-binding protein (CREB) con-
centration in hippocampal neurons and, more specifically,
to its phosphorylation into pCREB (Nibuya et al., 1996;
Thome et al., 2000; Nakagawa et al., 2002a; Tiraboschi
et al., 2004).
Recently, we have reported that central 5-HT4 receptors
exert an excitatory control on rat dorsal raphe nucleus
(DRN) 5-HT neuron firing activity (Lucas and Debonnel,
2002). In agreement with several anatomical studies
showing that the DRN is virtually devoid of 5-HT4 mRNA
and protein (Waeber et al., 1994; Vilaro et al., 1996), we
found that this control is indirect and involves 5-HT4
receptors located in the medial prefrontal cortex (Lucas
et al., 2005). More promising data were obtained after.
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showing that the 5-HT4-mediated positive control is al-
ready at its maximal level after 3 days and maintains the
same amplitude after long-term (21 days) administration
(Lucas et al., 2005). Obviously, such findings raise the
possibility that the stimulation of 5-HT4 receptors may
constitute a new way to achieve a rapid treatment for
depression.
In this study, we first assessed the AD potential of 5-HT4
agonists by using the forced swim test (FST) paradigm in
rats. Although this behavioral model works already in
subacute (30 min to 1 hr after injection) conditions and
therefore does not match the above-mentioned chronic
kinetics, it remains highly reliable in predicting the thera-
peutic potential of the tested compounds (Cryan et al.,
2002). Thereafter, we investigated whether the stimulation
of 5-HT4 receptors, after only 3 days of treatment with ag-
onists, is able to elicit the same functional, morphological,
and molecular changes as those induced by classical
ADs, including (1) desensitization of DRN 5-HT1A auto-
receptors, (2) enhanced inhibitory tonus mediated by
postsynaptic 5-HT1A receptors in the hippocampus, (3) in-
creased phosphorylation of CREB in hippocampal tissue,
and (4) the induction of hippocampal neurogenesis. For
this purpose, we used the selective 5-HT4 agonists RS
67333 (Eglen et al., 1995) and prucalopride (Briejer et al.,
2001); their effects were compared with those induced
by a 3 day treatment with citalopram, considered to be
the most selective SSRI (Sanchez and Hyttel, 1999). To
complete these experiments, we also used ‘‘chronic’’ be-
havioral models of depression, in which classical treat-
ments require continuous administration for 2–3 weeks
before any effect can be observed: the olfactory bulbec-
tomy (OBX) paradigm (Song and Leonard, 2005), chronic
mild stress (CMS)-induced anhedonia (Jayatissa et al.,
2006), and the novelty-induced hypophagia test (Loiseau
et al., 2006).
RESULTS
Effects of 5-HT4 Agonists and the SSRI Citalopram
in the FST
The efficacy of the compounds used was first tested in the
FST, which has proven to be a highly reliable predictor of
AD potential (Cryan et al., 2002). As shown in Figure 1A,
both prucalopride and RS 67333 strongly reduced the
time of immobility to a similar extent (around 50%): from
88.2 ± 7.2 s (control rats) to 43.4 ± 3.5 s and 42.7 ± 4.9 s,
respectively. In contrast, citalopram induced a weaker ef-
fect, reducing the time of immobility by only 23% (62.6 ±
5.4 s). This effect was not statistically different from
those of RS 67333 and prucalopride according to a global
statistical assessment (i.e., Tukey’s test performed after
a one-way ANOVA taking into account all four groups),
but, interestingly, the difference was significant when
citalopram was compared only to both 5-HT4 agonists
(p < 0.05 versus either prucalopride or RS 67333). Concern-
ing the influence on climbing, RS 67333 was more potentNeuFigure 1. Effect of Citalopram and 5-HT4 Agonists in the FST
(A) Effect of the selective 5-HT4 agonists RS 67333 (1.5 mg/kg, i.p.) and
prucalopride (2.5 mg/kg, i.p.) and of the SSRI citalopram (10 mg/kg,
i.p.) on the time spent immobile in the forced swimming test (FST).
All data are expressed as mean ± SEM of eight animals per group
and are from an observation of 4 min duration. Rats experienced a
pretest session (15 min) 24 hr before the test session. The different
compounds were administered 30 min before the test session.
(B) Effect of RS 67333, prucalopride, and citalopram on the time spent
climbing in the FST, in the same animals as in (A).
(C) Effect of RS 67333 (1.5 mg/kg, i.p.), prucalopride (2.5 mg/kg, i.p.),
and citalopram (10 mg/kg, i.p.) on horizontal locomotion in activity
chambers equipped with photoelectric cells to allow activity counts.
Data are expressed as mean ± SEM of eight animals per group and
are from an observation of 10 min duration. The different compounds
were administered 30 min before testing.
*p < 0.05, **p < 0.01 versus the vehicle, Tukey’s test.ron 55, 712–725, September 6, 2007 ª2007 Elsevier Inc. 713
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reached statistical significance (Figure 1B). The FST has
to be validated by also testing the influence of the com-
pounds used on motor behavior, because an increase in
motor activity could have also accounted for the observed
results (Cryan et al., 2002; Haddjeri et al., 2004). As shown
in Figure 1C, neither RS 67333 nor citalopram had any
effect on rat locomotion; however, prucalopride increased
significantly this parameter (by 78%). We could not there-
fore exclude that the behavioral effects induced by pruca-
lopride were at least in part related to a motor component.
Effect of a 3 Day Treatment with a 5-HT4 Agonist
on DRN 5-HT1A Autoreceptor Sensitivity
As previously reported (Sanchez et al., 2003), the acute,
i.v. administration of citalopram induced a dose-depen-
dent inhibition of 5-HT neuronal firing rate in naive animals,
with an ED50 of 130 ± 30 mg/kg and an ED100 of 280 mg/kg
(Figure 2). In rats treated with the selective 5-HT4 agonist
RS 67333 (1.5 mg/kg/day), these values were shifted to
the right, reaching 226 ± 26 and 430 mg/kg, respectively.
A statistical comparison revealed that the slopes of the
two dose-response curves were significantly different
(0.34 ± 0.03 versus –0.25 ± 0.02 for the vehicle and RS
67333 groups, respectively; F(1, 38) = 6.6, p = 0.014), con-
firming that the shift observed in the presence of RS 67333
was due to decreased sensitivity to citalopram. It is impor-
tant to mention that this shift was observed with a similar
amplitude in all neurons recorded from the RS 67333
group, their basal firing rate being either high (R2.0 Hz)
or low (%1.0 Hz) (see Discussion). The acute inhibitory ef-
fect produced by an SSRI on DRN 5-HT neuronal activity
results from increased extracellular levels of 5-HT, due to
the blockade of its reuptake, and is selectively related to
the stimulation of somatodendritic 5-HT1A autoreceptors
(Hajos et al., 1999). The degree of inhibition induced by
citalopram has therefore been used as a reliable index of
their sensitivity (Arborelius et al., 2004; Sanchez et al.,
2003). It appears that a 3 day treatment with a 5-HT4
receptor agonist is sufficient to desensitize 5-HT1A autor-
eceptors in the DRN.
Effect of 3 Day Treatments with 5-HT4 Agonists
and the SSRI Citalopram on the Response
of Hippocampal Pyramidal Neurons
to a 5-HT1A Antagonist
The firing activity of dorsal hippocampus pyramidal neu-
rons was then recorded in the CA3 subfield, before and
after systemic administration of the selective 5-HT1A an-
tagonist WAY 100635. This protocol has proved useful in
revealing an increased tonic stimulation of inhibitory post-
synaptic 5-HT1A receptors, a common and selective trait
for all AD treatments (Haddjeri et al., 1998; Besson et al.,
2000; Blier and Ward, 2003). As illustrated in Figure 3A,
cumulative (100–500 mg/kg) i.v. injections of WAY 100635
had no effect on CA3 pyramidal neurons in vehicle-treated
animals, confirming that, in normal conditions of anes-
thesia, there is virtually no 5-HT1A tone in this brain area714 Neuron 55, 712–725, September 6, 2007 ª2007 Elsevier In(Haddjeri et al., 1998; Besson et al., 2000). However,
WAY 100635 had a dose-dependent excitatory effect in
rats treated with either RS 67333 (1.5 mg/kg/day) or
prucalopride (2.5 mg/kg/day) (Figure 3A). The effect was
moderate in the prucalopride group, reaching statistical
significance only after the highest cumulative i.v. dose of
WAY 100635 (500 mg/kg), at 191% (±31%) of baseline.
In the RS 67333 group, all three cumulative doses of
200, 300, and 500 mg/kg strongly increased the firing ac-
tivity of CA3 pyramidal neurons to 276% (±52%), 378%
(±43%), and 445% (±60%) of basal values, respectively
(Figures 3A and 3B). Three days of treatment with 5-HT4
agonists was therefore sufficient to induce the apparition
of a 5-HT1A-mediated tonic inhibitory effect on CA3 pyra-
midal neurons. In contrast, a 3 day treatment with citalo-
pram did not affect the influence exerted by endogenous
5-HT on CA3 5-HT1A receptors. Indeed, as shown in
Figure 3A, WAY 100635 induced only a marginal (not
statistically significant) increase of CA3 pyramidal neuron
activity in the citalopram group, reaching around 135%
of baseline after the highest cumulative dose of 500 mg/kg.
The decreased basal activity of CA3 pyramidal neurons
after 3 days of treatment with 5-HT4 agonists was con-
firmed by comparing the ejection currents of quisqualate
required to perform the experiments. Indeed, as most
hippocampal pyramidal neurons are not spontaneously
active under chloral-hydrate anesthesia, a leak or a small
ejection current (0 to 2 nA) of quisqualate (through the
use of a multibarrelled electrode and microiontophoretic
‘‘pumps,’’ see Experimental Procedures) is necessary to
Figure 2. Sensitivity of 5-HT1A Autoreceptors
Dose-response curves illustrating the effect of cumulative intravenous
doses of citalopram on dorsal raphe nucleus (DRN) 5-HT neuron aver-
age (mean ± SEM) firing rate, expressed as percentage of basal activity,
in rats treated with the selective 5-HT4 agonist RS 67333 (1.5 mg/kg/
day, 3 days, n = 5) or its vehicle (n = 5). Single-cell extracellular record-
ings were performed in the DRN of chloral-hydrate anesthetized rats
by using single-barrel glass microelectrodes, and 5-HT neurons were
identified according to the classical criteria (see Experimental Proce-
dures). RS 67333 was administered through the use of osmotic mini-
pumps that were inserted subcutaneously in the region of the back.
Recordings were performed with the minipumps still in place.c.
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(A) Effect of cumulative intravenous doses of the selective 5-HT1A an-
tagonist WAY 100635 on the average (mean ± SEM) firing activity of
hippocampal pyramidal neurons of the CA3 subfield in rats treated
with the selective 5-HT4 agonists RS 67333 (1.5 mg/kg/day, 3 days,
n = 5) and prucalopride (2.5 mg/kg/day, 3 days, n = 5), with the SSRI
citalopram (10 mg/kg/day, 3 days, n = 6), or with the vehicle (n = 5). Sin-
gle-cell extracellular recordings were performed in the CA3 region of
chloral-hydrate-anesthetized rats by using multiple-barrel glass micro-
electrodes combined with microiontophoretic pumps (with the central
barrel used for recordings). Pyramidal neurons were identified accord-
ing to the classical criteria (see Experimental Procedures). All com-
pounds were administered through the use of osmotic minipumps
that were inserted subcutaneously in the region of the back. Record-
ings were performed with the minipumps still in place. *p < 0.05,
**p < 0.01, ***p < 0.001 versus control, Tukey’s test.
(B) A typical example (integrated firing rate histogram) showing the
response of a single pyramidal neuron to cumulative doses of WAY
100635 in the RS 67333-treated group. Please note the high values
of ejection currents required for quisqualate.
(C) A typical example showing the response of a single pyramidal neu-
ron to cumulative doses of WAY 100635 in a rat coadministered with
RS 67333 (same treatment as in (A) and the 5-HT depleter parachlor-Neuactivate them within their physiological firing range of 10–
15 Hz (Haddjeri and Blier, 1995; Haddjeri et al., 1998). In
the RS 67333-treated group, their excitability was re-
duced to such an extent that currents as high as
–4 to –6 nA were required to obtain similar basal values
(Figure 3B). Again, the effect was less prominent in the
prucalopride group, as the required currents were be-
tween –2 and –4 nA (data not shown). Finally, the currents
needed for quisqualate ejection in the citalopram group
were similar to those used in control animals (0 to –2 nA,
data not shown).
Involvement of Endogenous 5-HT
and Hippocampal 5-HT1A Receptors in the Effect
of 5-HT4 Agonists
The most logical explanation for the above results would
be that short-term treatments with 5-HT4 agonists in-
duced an increase of 5-HT release in the CA3 subregion,
which in turn resulted in an enhanced stimulation of post-
synaptic 5-HT1A receptors located on pyramidal neurons.
This interpretation is consistent with our own previous
findings showing that both acute and chronic (3 day)
administration of these compounds augment DRN 5-HT
neuronal firing activity (Lucas and Debonnel, 2002; Lucas
et al., 2005). It is also in keeping with observations from
a single in vivo microdialysis study where acute systemic
injection of preferential 5-HT4 agonists increased hippo-
campal 5-HT efflux (Ge and Barnes, 1996). To further ad-
dress this possibility, two additional series of experiments
were conducted. First, the role of endogenous 5-HT was
assessed by using the same protocol as above in rats
cotreated with RS 67333 (or its vehicle) and the 5-HT
depleter parachlorophenylalanine (pCPA). In the vehicle
group, pCPA had no effect per se on either CA3 neuron fir-
ing activity or their response to WAY 100635 (data not
shown; n = 4). However, as shown in Figure 3C, pCPA to-
tally abolished the facilitatory action of WAY 100635 in rats
treated with RS 67333 (n = 5). The ejection currents of
quisqualate that are needed to activate CA3 pyramidal
neurons were, in this case, similar to those used in con-
trols (0 to –2 nA; Figure 3C). We then tested the ability of
a local application of WAY 100635 directly into the CA3
subfield through the use of microiontophoresis to modify
the effect of a 5-HT4 agonist. We chose not to use the
previous protocol (i.e., chronic treatments), because, as
shown above, the required quisqualate currents differ be-
tween the experimental groups. Even though all currents
were balanced, it was not possible to exclude the possibil-
ity that the amount of quisqualate present in the vicinity of
the electrode may have an influence on the quantity of
WAY 100635 actually ejected and/or on its ability to act
on pyramidal neurons. For this reason, we used prucalopr-
ide acutely in naive rats, at a dose known to induce both
ophenylalanine (pCPA; 150 mg/kg, i.p., once daily 72, 48, and 24 hr
before the recordings). In this case, the ejection currents required for
quisqualate were similar to those used in control animals.ron 55, 712–725, September 6, 2007 ª2007 Elsevier Inc. 715
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campal Effect of RS 67333
(A and C) A typical example (integrated firing
rate histogram) showing the response of a sin-
gle hippocampal pyramidal neuron of the CA3
subfield to an acute, intravenous administra-
tion of the selective 5-HT4 agonist prucalopride
(1000 mg/kg) and its reversal by local, microion-
tophoretic application of the selective 5-HT1A
antagonist WAY 100635 (A) or systemic injec-
tion of the selective 5-HT4 antagonist GR
125487 (1000 mg/kg, i.v.) (C). Single-cell extra-
cellular recordings were performed in the CA3
region of chloral-hydrate-anesthetized rats by
using multiple-barrel glass microelectrodes
combined with microiontophoretic pumps
(with the central barrel used for recordings).
Pyramidal neurons were identified according
to the classical criteria (see Experimental
Procedures).
(B and D) Summary of the effects shown in (A)
and (C), respectively. Bar histograms represent
the mean (±SEM) percentage effect, calculated
for each neuron with respect to its basal firing
rate (i.e., 100% value), and the number in
each column represents the number of
neurons tested. *p < 0.05 versus basal value,
one-way ANOVA.a significant and selectively 5-HT4-dependent augmenta-
tion of DRN 5-HT neuronal activity (1000 mg/kg, i.v.) (Lucas
and Debonnel, 2002). Of the 38 pyramidal neurons re-
corded, 21 were unaffected by prucalopride, whereas
the remaining 17 (45% of total) were clearly inhibited, dis-
charging at only 46% (±5.6%) of predrug values (Figure 4).
This inhibition was totally reversed by the microiontopho-
retic application of WAY 100635 (1 nA), devoid of any
effect by itself (Figures 4A and 4B). The involvement of
5-HT4 receptors in the action of prucalopride was con-
firmed, as it was abolished by systemic administration of
the selective 5-HT4 antagonist GR 125487 (1000 mg/kg,
i.v.; Figures 4C and 4D).
Effect of 3 Day Treatments with 5-HT4 Agonists
and theSSRI CitalopramonCREBPhosphorylation
in the Hippocampus
Having confirmed a critical role for DRN-hippocampus
5-HT transmission in mediating the effects of 5-HT4
agonists, the next step was to determine whether the
observed changes in 5-HT neurotransmission were
accompanied by a modification in molecular dynamics
downstream of receptor activation. It has been previously
shown that ADs that enhance 5-HT extracellular levels,
such as SSRIs, promote cAMP signaling in hippocampal
neurons and increase CREB activation—an effect that be-
comes evident only after 2 weeks of chronic administra-
tion (Nibuya et al., 1996; Thome et al., 2000; Tiraboschi
et al., 2004). Thus, we were interested in finding out
whether 5-HT4 agonists were able to produce a faster ac-
tivation of this transcription factor. CREB activation was
measured by immunoblot using state-specific antibodies
that label its phosphorylated active form. In keeping with716 Neuron 55, 712–725, September 6, 2007 ª2007 Elsevier Incprevious reports (Pliakas et al., 2001), pCREB appeared
as an immunoreactive band at 46 kDa. A band corre-
sponding to the total amount of transcription factor pres-
ent in the sample was observed at similar molecular
weight (Figure 5). While maintaining total CREB levels un-
changed (optic density: control 0.40 ± 0.03, prucalopride
0.32 ± 0.02, RS 67333 0.39 ± 0.03, citalopram 0.37 ±
0.02; Figure 5), a 3 day treatment with RS 67333 and
prucalopride enhanced pCREB immunoreactivity. Corre-
sponding pCREB/CREB ratios for different treatments
are shown (Figure 5) and indicate that only exposure to
RS 67333 significantly enhanced the proportion of CREB
in its phosphorylated state within the hippocampus. In-
deed, the mean values of ratios were 0.18 ± 0.01, 0.30 ±
0.07, and 0.37 ± 0.07 in the control, prucalopride, and
RS 67333 groups, respectively. The increase observed
in RS 67333-treated animals (+105%) was statistically sig-
nificant (p < 0.05, Dunnett’s test after significant one-way
ANOVA), whereas the +66% effect found in the prucalopr-
ide group did not reach statistical significance (p = 0.06).
Citalopram in contrast left pCREB values unchanged.
Effect of a 3 Day Treatment with Either RS 67333
or Citalopram on Hippocampal Neurogenesis
Classical ADs (and especially SSRIs) promote adult neu-
rogenesis in the hippocampus (Malberg et al., 2000;
Duman et al., 2001; Nestler et al., 2002; Castre´n, 2004).
Increased neurogenesis occurs predominantly in the sub-
granular zone (SGZ) of the dentate gyrus (Malberg et al.,
2000; Nakagawa et al., 2002a; Santarelli et al., 2003)
and requires at least 2 or 3 weeks of chronic treatment
(Malberg et al., 2000; Nakagawa et al., 2002a; Santarelli
et al., 2003). Remarkably, a 3 day treatment with RS.
Neuron
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yuridine (BrdU)-positive cells in the SGZ (Figure 6). In the
RS 67333 group, the stereological count indicates that
the volumetric density of BrdU-positive cells (per mm3)
increased to 128% of vehicle values (19,120 ± 723 versus
14,955 ± 699; p < 0.01, Tukey’s test; see inset in Figure 6).
Detailed morphological analysis of the histological sec-
tions revealed that these cells were grouped in clusters
of six to ten clones following the RS 67333 treatment, sug-
gesting an acute induction of mitotic activity (Figure 6A).
Such clusters of BrdU-positive cells were never observed
in the vehicle group (Figure 6C) and were sparse in the cit-
alopram group (Figure 6B). In comparison to RS 67333,
a 3 day treatment with citalopram had no effect on the num-
ber of BrdU-positive cells (15,146 ± 753, hence 101% of
control values; Tukey’s test, n.s; inset in Figure 6). The
mean coefficient of error (Luk and Sadikot, 2001) of BrdU-
IR granule layer cell counts was 0.09 ± 0.005 (n = 12).
Effect of Chronic Treatmentswith Either RS67333
or Citalopram on the Hyperlocomotion Induced
by Olfactory Bulbectomy
As previously reported (Cryan et al., 1999), 14 days after
surgery, olfactory bulbectomized (OBX) rats displayed
a significant increase of locomotor activity with respect
to sham-operated animals (Figure 7A). Results were
Figure 5. Effect of Citalopram and 5-HT4 Agonists on pCREB
Effect of the selective 5-HT4 agonists RS 67333 (1.5 mg/kg/day,
3 days) and prucalopride (2.5 mg/kg/day, 3 days) and of the SSRI cit-
alopram (10 mg/kg/day, 3 days) on the activation of CREB in hippo-
campal tissue, assessed by measuring phosphoCREB (pCREB)
immunoreactivity. CREB phosphorylation was normalized according
to the amount of protein present in each sample by expressing the
data as a ratio of pCREB over total CREB immunoreactivity (see Exper-
imental Procedures for more details). Results represent mean ± SEM
for the number of experiments indicated for each treatment. Inset
shows representative examples of pCREB immunoreactivity for differ-
ent treatment conditions indicated on the histogram. All compounds
were administered through the use of osmotic minipumps that were
inserted subcutaneously in the region of the back. *p < 0.05 versus
vehicle, Tukey’s test.Neexpressed as the distance covered over a 5 min period
and were found to be 51% higher in the OBX-vehicle
group than those of the sham group (3730 ± 400 cm ver-
sus 2466 ± 328 cm, p < 0.05, Tukey’s test). More interest-
ingly, a 3 day treatment with RS 67333 strongly reduced
this augmentation, by more than one-half. As shown in
Figure 7A, the distance covered in the OBX-RS 67333
group was 3155 ± 241 cm, reaching 24% above sham
values. This result was not statistically different from that
obtained in OBX-vehicle animals (Tukey’s test, n.s.), but
there was also no difference (Tukey’s test, n.s.) with
sham-operated rats, indicating a marginal increase only.
Figure 6. Effect of Citalopram and RS 67333 on Mitogenesis
Effect of RS 67333 (1.5 mg/kg/day, 3 days) and citalopram (10 mg/kg/
day, 3 days) on the number of BrdU-positive cells in the subgranular
zone (SGZ) of the hippocampus.
(A–C) Photomicrographs (magnification: 103 and 1003 for the small
rectangles) representative of the RS 67333, citalopram, and control
groups, respectively. Please note the clusters of positive cells found
in the presence of RS 67333 (small rectangles). Inset shows the sum-
mary (mean ± SEM) of the effects of RS 67333 and citalopram on the
volumetric density of BrdU-positive cells (per mm3), as measured by
a stereological count (see Experimental Procedures for more details)
(n = 4 in all groups). RS 67333 and citalopram were administered
through the use of osmotic minipumps that were inserted subcutane-
ously in the region of the back. Rats received intraperitoneal injections
of BrdU at the dose of 50 mg/kg twice daily (8 hr interval), starting from
the day of minipump insertion until day 2 postsurgery.
**p < 0.01 versus vehicle, Tukey’s test.uron 55, 712–725, September 6, 2007 ª2007 Elsevier Inc. 717
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very similar to those found in the OBX-vehicle group
(3870 ± 345) and was significantly different from the
sham (+57%; p < 0.05, Tukey’s test).
To confirm the validity of our experimental conditions,
animals were also tested after 14 days of treatment with
the compounds used. Indeed, it is well established that,
after such a period of chronic administration, SSRIs are
able to reduce the effect of OBX on locomotion (Song
and Leonard, 2005). As illustrated in Figure 7B, the values
found in OBX-citalopram rats were only 18% above those
of their sham-operated counterparts and were not signifi-
cantly different from them (Tukey’s test, n.s.). In addition,
further confirming the promising results observed after 3
days, a 14 day treatment with RS 67333 totally abolished
the hyperlocomotor effect of the bulbectomy, with a dis-
tance covered very similar to that of sham-operated
animals (2649 ± 326 and 2619 ± 248 cm, respectively)
Figure 7. Effect of Citalopram and RS 67333 in the OBXModel
Effect of RS 67333 (1.5 mg/kg/day) and citalopram (10 mg/kg/day) on
the locomotor activity in olfactory bulbectomized (OBX) rats. The OBX
surgery was performed by using a suction strategy (see Experimental
Procedures for more details), and animals were allowed to recover for
a period of 11 days. RS 67333 and citalopram were then administered
through the use of osmotic minipumps that were inserted subcutane-
ously in the region of the back, and locomotion was measured in an
open-field apparatus both 3 days (A) and 14 days (B) after the insertion.
Results represent the mean (±SEM) values of eight animals per group.
*p < 0.05 versus sham, #p < 0.05 versus OBX-vehicle, Tukey’s test.718 Neuron 55, 712–725, September 6, 2007 ª2007 Elsevier Inand statistically different from that of OBX-vehicle rats
(p < 0.05, Tukey’s test).
Effect of Chronic TreatmentswithEither RS67333
or Citalopram on the Reduction of Sucrose Intake
Induced by Chronic Mild Stress
As shown in Figure 8, 2 weeks of initial exposure to CMS
resulted in a strong reduction of sucrose intake. When
Figure 8. Effect of Citalopram andRS 67333 in theCMSModel
Effect of repeated administrations of RS 67333 (0.75 mg/kg/day) and
citalopram (10 mg/kg/day) on sucrose intake (mean ±SEM) in the
chronic mild stress (CMS) model. Rats were separated into two
groups, one undergoing a CMS protocol optimized in our laboratory
(see Experimental Procedures for more details), while the other one
was left unchallenged. After 2 weeks of initial exposure to CMS, the
stressed group (n = 40) was subdivided into three subgroups: RS
67333 (n = 16), citalopram (n = 16), and vehicle (n = 8). Pharmacological
treatments started on day 1, and consisted of one daily i.p. injection in
the morning. The stress procedure was continued thereafter, during
the entire period of treatment. Panel (A) illustrates the effect of RS
67333 (n = 9) and citalopram (n = 8) in ‘‘responders,’’ i.e., rats in which
RS 67333 and citalopram had a significant effect on sucrose intake
(see Results for more details). ‘‘Nonresponders’’ are shown in panel
(B). For each time point, *p < 0.05, **p < 0.01, and ***p < 0.001 versus
the stressed vehicle group, Tukey’s test. The nonstressed vehicle
group is composed of ten animals.c.
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and unchallenged (nonstressed vehicle group) animals on
day 3 (i.e., 3 days before starting chronic treatments),
the amplitude of decrease was revealed to be higher
than 50% (6.7 ± 0.05 versus 14.3 ± 0.88 g of sucrose con-
sumed). A chronic treatment with either RS 67333 (0.75
mg/kg/day) or citalopram (10 mg/kg/day) induced a rever-
sion of this effect in about 50% of the stressed animals
(‘‘responders;’’ Figure 8A), whereas the remaining ones
did not respond (‘‘nonresponders;’’ Figure 8B). Such a
bimodal distribution has already been observed in our
experimental conditions by using escitalopram, the S en-
antiomer of citalopram (Jayatissa et al., 2006). It appears
to be a stable, highly reproducible phenomenon, indepen-
dent from the dose of SSRI administered (Jayatissa et al.,
2006). Together with the present data, this suggests that
the existence of two populations of rats (one-half respond-
ing to a putative AD, while the other one will not) is a gen-
eral feature of our CMS protocol and that it is not related to
the use of a specific type of molecule. Also, citalopram
and RS 67333 had no influence on their own on sucrose
intake in nonstressed animals (data not shown, n = 10
for each).
Even more interestingly, our results indicate that the
effect of RS 67333 had a much more rapid onset of action
than citalopram. Thus, after only 3 days of treatment,
sucrose intake in the RS 67333 group was already signif-
icantly higher than in the vehicle (77% versus 51% of non-
stressed animal values at the same time point, p < 0.05,
Tukey’s test after significant one-way ANOVA). By con-
trast, sucrose intakes in citalopram- and vehicle-treated
rats were very similar at that time (52% versus 51%,
Tukey’s test, n.s.). On day 10 of treatment, the citalopram
group was still not statistically different from the vehicle
group (Tukey’s test, p = 0.12), even though sucrose intake
was substantially enhanced (74% versus 47% of non-
stressed animal values). On the other hand, there were
no more significant differences between RS 67333-
administered and unchallenged rats (90% versus 100%).
Actually, a more detailed examination of Figure 8A reveals
that sucrose intake in the RS 67333 group was somewhat
lower than in the two other groups of stressed animals (5.6
versus 6.7–7.1 g) on day3, i.e., before any pharmacolog-
ical treatment had been started. A very similar difference
of around 1 g was still observable on day 10, this time
with respect to unchallenged animals (13.4 versus 14.8 g).
These comparisons strongly suggest that a 10 day
treatment with RS 67333 was sufficient to fully reverse
the inhibitory effect of CMS on reward. By contrast, citalo-
pram induced a comparable, full reversion of CMS influ-
ence only after 24 days of continuous administration
(Figure 8A).
Effect of RS 67333 and the SSRI Fluoxetine
in the Novelty-Induced Hypophagia Test
In this test, we used an acute injection of diazepam (2 mg/
kg, i.p.), a typical anxiolytic of the benzodiazepine class,
as a positive control. Indeed, as previously reportedNeur(Loiseau et al., 2006), this treatment induced a strong in-
crease of food consumption in food-deprived animals
(see Figure S1 in the Supplemental Data available with
this article online). By contrast, neither fluoxetine (10 mg/
kg/day, 14 days) nor RS 67333 (1.5 mg/kg/day, 3 days)
modified this parameter in our experimental conditions
(Figure S1). It appears therefore that, similarly to SSRIs,
RS 67333 has poor influence on anxiety-related compo-
nents of ‘‘depression-like’’ behaviors in Sprague-Dawley
rats (see Discussion for details).
DISCUSSION
The first result of this study indicates that 5-HT4 agonists
have properties common to classical ADs in the FST, sug-
gesting that they may have a potential interest for the
treatment of depression. The reduction of immobility
time that we found in this test for both RS 67333 and pru-
calopride (50%; Figure 1) was of higher amplitude than
the one typically observed 30–60 min after single injec-
tions of SSRIs (around –25%, not significant in all the stud-
ies) (Cryan et al., 2002; Haddjeri et al., 2004; present
study). The effect induced by prucalopride, however,
was also paralleled by an increase of motor activity. It is
possible that the low affinity displayed by this compound
for dopamine-D4 receptors (Briejer et al., 2001) may ac-
count for this result, because even a weak stimulation of
D4 receptors has been reported to facilitate locomotion
(Nayak and Cassaday, 2003). Whatever its exact causes,
this nonspecific action of prucalopride prompted us to
not use this drug at a dose higher than 2.5 mg/kg, even
if it is likely not maximal with respect to 5-HT4 receptor
stimulation. Indeed, prucalopride can induce robust cen-
tral effects at a dose as high as 5 mg/kg, i.p., in a manner
that appears to be still selective for 5-HT4 receptors (i.e.,
blocked by selective 5-HT4 antagonists) (Porras et al.,
2002). This result on locomotion also constitutes the
main reason for the present study to be more focused
on the use of RS 67333; prucalopride has been used alone
only when necessary and if the 5-HT4 dependency of the
effect to be produced had been previously established
(see below).
Most importantly, our results indicate that electro-
physiological, molecular, morphological, and behavioral
changes that have previously been specifically linked to
long-term treatment with SSRIs are already present after
only 3 days when using 5-HT4 agonists. Consistent with
the facilitatory action displayed by the latter, at the same
dose regimen, on DRN 5-HT neuron firing rate (Lucas
et al., 2005), we found that the DRN-hippocampus 5-HT
transmission was deeply modified by 5-HT4 receptor acti-
vation. The shift to the right in the ability of acutely admin-
istered citalopram to inhibit 5-HT neuron firing rate
(Figure 2) clearly suggests a decreased sensitivity of
somatodendritic 5-HT1A autoreceptors. It could still be
argued that this shift only resulted from the arithmetic
sum of two opposite influences, namely an inhibition
caused by citalopram versus the facilitatory effect of theon 55, 712–725, September 6, 2007 ª2007 Elsevier Inc. 719
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neurons recorded (see Results). We have previously
shown that a subpopulation, representing about one-half
of DRN 5-HT neurons and discharging at a low (%1.0
Hz) basal frequency, is not sensitive to 5-HT4 receptor
stimulation (Lucas and Debonnel, 2002). It appears there-
fore that the reduced sensitivity to citalopram observed
in all neurons was related to a ‘‘true’’ desensitization of
5-HT1A autoreceptors. This strongly suggests that 5-HT
extracellular levels were enhanced in the DRN after a
3 day treatment with RS 67333, as already proposed to
explain the desensitization induced by SSRIs (Blier and
de Montigny, 1999; Artigas et al., 2002), which is known
to progress gradually, being observable only after 2–3
weeks (Blier and de Montigny, 1994; El Mansari et al.,
2005). The more rapid desensitization observed with RS
67333 may be due to the different characteristics of the
mechanisms involved: rather than a passive elevation of
5-HT extracellular levels consequent to the blockade of
5-HT reuptake sites and related to a slow diffusion within
extracellular space, the activation of 5-HT neuronal firing
rate elicited by 5-HT4 agonists should facilitate a true,
active release of 5-HT within the DRN.
This possibility is also consistent with our conclusion
that 5-HT release was enhanced in projection areas,
more particularly the dorsal hippocampus, after a 3 day
treatment with 5-HT4 agonists. This enhancement was
unveiled by the manifestation of an inhibitory tonus, medi-
ated by endogenous 5-HT through the stimulation of post-
synaptic 5-HT1A receptors (Figure 3). Such an effect has
already been observed with numerous classical AD treat-
ments, but only after 2–3 weeks of sustained administra-
tion (Haddjeri et al., 1998; Besson et al., 2000; El Mansari
et al., 2005). In agreement with these previous studies, our
results indicate that citalopram was ineffective when
administered for 3 days. Moreover, in the case of RS
67333, the inhibitory tonus appeared to be stronger than
that induced by a 21 day treatment with SSRIs: the selec-
tive 5-HT1A antagonist WAY 100635 was able to increase
CA3 pyramidal neuron activity up to 440% of predrug
values (Figure 3), whereas this disinhibition has been re-
ported to reach a maximum of 200% after 3 weeks of
treatment with the SSRI paroxetine or other classical AD
treatments (Haddjeri et al., 1998). The effect of prucalopr-
ide, on the other hand, was more modest, as a high cumu-
lative dose of WAY 100635 was needed to unveil the
existence of the 5-HT1A-mediated tonus. The difference
of amplitude between the effects of the two 5-HT4 ago-
nists is in agreement with their respective action on DRN
5-HT neuron mean firing rate: prucalopride enhanced
this parameter by about 40%–45%, whereas the effect
of RS 67333 reached 70% (Lucas et al., 2005). It is there-
fore possible that the augmentation of 5-HT release in-
duced by prucalopride in the hippocampus was less
important than that elicited by RS 67333. It is of interest
to be reminded that the dose of prucalopride used for
these chronic treatments is relatively low (see above). In
contrast with these modest short-term chronic effects,720 Neuron 55, 712–725, September 6, 2007 ª2007 Elsevier Incthe acute injection of 1000 mg/kg, i.v., prucalopride was
able to inhibit the activity of CA3 pyramidal neurons by al-
most 50% (Figure 4) (in 45% of the cases; see the Supple-
mental Discussion, Part 1 for a detailed discussion on this
latter point). We already knew (see Results) that this acute
dose of prucalopride produces a strong increase of DRN
5-HT neuronal activity (around 100%), which is totally
blocked by 5-HT4 antagonists. Thus, because we did
not know about the i.v. dose of RS 67333 required to ob-
tain a similar effect, in this particular case, we decided to
conduct the experiments with prucalopride, even though
RS 67333 was preferred in the rest of the study (see our
statement concerning the two drugs, above). These find-
ings on 5-HT1A neurotransmission are of high importance
in a therapeutic perspective—an increased 5-HT1A-medi-
ated inhibition of hippocampal cells being considered a
crucial step to obtain the beneficial effects of ADs such
as SSRIs (Haddjeri et al., 1998; Santarelli et al., 2003;
Castre´n, 2004).
In line with this statement, we found that both pruca-
lopride and RS 67333 were able, after only 3 days of
chronic administration, to enhance the pCREB/CREB
ratio in hippocampal tissue. Such an increase has also
been reported to constitute a specific marker of AD action
in rat brain (Nibuya et al., 1996; Thome et al., 2000; Naka-
gawa et al., 2002a; Tiraboschi et al., 2004) but, again, has
never been observed before 1.5–2 weeks of treatment
(Nibuya et al., 1996), as confirmed by the lack of effect
of citalopram observed in the present study. The effect
of RS 67333 was stronger than that of prucalopride, paral-
leling electrophysiological results, but more importantly, it
was also of higher amplitude (+105%; Figure 5) than the
previously reported increase induced by long-term SSRI
treatment (+20%–30%) (Tiraboschi et al., 2004). The pos-
sibility that this higher amplitude is due to a dual action of
5-HT4 agonists cannot be excluded, as a number of data
suggest that the stimulation of 5-HT4 receptors located
on pyramidal neurons may activate CREB (Duman,
1998). This direct effect could amplify the ‘‘indirect
5-HT1A agonist’’ effect of 5-HT4 agonists. Indeed, the
hypothesis that hippocampal 5-HT1A and 5-HT4 receptors
exert such a synergetic, facilitatory control on CREB acti-
vation has already been proposed (Duman, 1998). Several
studies have shown that the proneurogenetic action of
SSRIs is directly related to their ability to phosphorylate
CREB (Nakagawa et al., 2002a, 2002b) and that increased
neurogenesis is crucial for the AD potential of these com-
pounds (Santarelli et al., 2003). We therefore tested
whether a 3 day treatment with RS 67333, the most active
of the 5-HT4 agonists used in electrophysiological and
molecular experiments, was also able to facilitate neuro-
genesis in the hippocampus. The results shown in Figure 6
clearly confirm the ability of such a treatment to enhance
cell division and proliferation in the SGZ. The increase ob-
served in the stereological count of BrdU-positive cells
(+28%) was very similar to that previously reported after
a 14 day treatment with the SSRI fluoxetine (+35%) (Mal-
berg et al., 2000). As opposed to RS 67333, citalopram.
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istration. To our knowledge, this is the first time that a com-
pound known to facilitate 5-HT transmission has been
shown to activate adult hippocampal neurogenesis so
rapidly. So far, the quickest effect reported was 11 days
for fluoxetine, which was inactive at 5 days (Santarelli
et al., 2003); with other ADs, neurogenesis occurred only
after 2–3 weeks (Malberg et al., 2000; Castre´n, 2004).
A short paragraph on the possible conceptual conse-
quences of this result is proposed in the Supplemental
Discussion, Part 2.
Finally, the fast-acting AD potential of 5-HT4 agonists
was further confirmed by several ‘‘chronic’’ behavioral
models of depression. In the OBX paradigm, lesioned an-
imals display a higher spontaneous locomotor activity
than their sham counterparts when placed in an open field
in conditions of high illumination. This effect is believed to
be due to a deficit of habituation in a stressful environment
and is reversed by long-term (2–3 weeks), but not acute,
treatments with SSRIs (Song and Leonard, 2005). Accord-
ingly, our results show that the continuous administration
of citalopram to OBX rats, totally ineffective after 3 days,
induces an important reduction of the locomotor hyperac-
tivity after 14 days (Figure 7). However, and more impor-
tantly, they also show that a 3 day treatment with RS
67333 is already able to counteract the effect of bulbec-
tomy, with an efficacy comparable to that of 14 days of
citalopram. This quicker onset of action was further con-
firmed by the fact that, after 14 days of RS 67333, the
hyperlocomotion was totally abolished. The kinetics
observed in the CMS studies were very similar. This test
is thought to constitute a model for the anhedonic compo-
nent of depression, and SSRIs have proved effective to
progressively suppress the adverse effect of CMS on su-
crose intake (Jayatissa et al., 2006). In keeping with the
present results (Figure 8), these molecules induce a full
reversion only after 2 or 3 weeks of chronic administration
(Jayatissa et al., 2006). In the same conditions, RS 67333
was already able to counteract the influence of CMS after
3 days, and the reversion appeared to be total after 1 week
(Figure 8). That the kinetics of OBX and CMS tests were so
similar is even more remarkable when considering that the
dose of RS 67333 selected for the latter was only 0.75 mg/
kg/day. Indeed (see Experimental Procedures), we chose
to administer the animals with half the dose of RS 67333
used in the rest of the study. The fact that RS 67333 was
still effective suggests that the potential AD properties
of 5-HT4 agonists may be quite strong. Once again, the
5-HT4 agonist appeared to be four to five times more rapid
than the SSRI to display antidepressant-like properties,
in true, ‘‘chronic’’ behavioral models of depression. The
picture was different when considering the results of the
novelty-induced hypophagia test. Neither the typical
SSRI fluoxetine (14 days) nor RS 67333 (3 days) were
able to increase the amount of food consumed by rats in
a novel environment, as opposed to the anxiolytic diaze-
pam. However, whereas OBX and CMS are believed to
represent ‘‘affective’’ components of depression (i.e.,Nehabituation to stressful stimuli and ability to cope there-
with and anhedonia; see above), novelty-induced hypo-
phagia is considered to be more an ‘‘anxiety-depression’’
model (David et al., 2007), or even for others, a test of anx-
iety as such (Bodnoff et al., 1989). Moreover, depending
on the strain and/or the species studied, it can be affected
by SSRIs independently from changes in central 5-HT
function or hippocampal neurogenesis (Holick et al.,
2007). Conversely, the effects of SSRIs in both the OBX
and CMS models appear to be paralleled by an increase
of mitotic activity within the hippocampus (Jayatissa
et al., 2006; Jaako-Movits et al., 2006). It can therefore
not be excluded that, in Sprague-Dawley rats, novelty-
induced hypophagia is poorly sensitive to an enhanced
5-HT neurotransmission. Alternatively, it is also possible
that both SSRIs and 5-HT4 agonists are less effective on
‘‘anxiety-related’’ components of depression in this rat
strain.
Overall, the results presented here show a clear poten-
tial for 5-HT4 agonists as putative antidepressants with
a rapid onset of action. According to the different experi-
mental models studied, they may act four to seven times
more rapidly than classical ADs and possibly with greater
efficacy. Presently, RS 67333 and prucalopride are virtu-
ally the only available selective 5-HT4 agonists that are
able to cross the blood-brain barrier; we hope that this
study may contribute to the development of new com-
pounds, so that clinical trials can be conducted in the
near future.
EXPERIMENTAL PROCEDURES
Animals
Experiments were carried out in male Sprague-Dawley (Charles River,
St-Constant, Que´bec, Canada, and Harlan, Gannat, France) or Wistar
(Taconic, Denmark) rats, weighing 250–300 g and kept under standard
laboratory conditions (12:12 light-dark cycle with free access to food
and water). Different rats were used for the FST and the locomotor
activity responses. For CMS experiments, the animals were singly
housed, except when grouping was applied as a stress parameter.
All animals were handled according to the guidelines approved by
the faculty ethical committees of our institutions.
Drugs and Chemicals
The following compounds were used: GR 125487 sulphamate, pruca-
lopride monohydrochloride, citalopram hydrobromide (gifts from
Glaxo, Janssen, and Lundbeck laboratories, respectively), RS 67333
hydrochloride (Tocris Cookson Inc., Ellisville, MO), WAY 100635 hy-
drochloride (Research Biochemicals, Natick, MA), pCPA methyl ester
hydrochloride, BrdU (Sigma-Aldrich Canada, Oakville, Ontario, Can-
ada). BrdU was diluted in Tris-buffered saline (0.1 M in NaCl 0.9%
[ph 7.6]), and the other compounds in distilled water. All drug dosages
refer to the free base. For chronic treatments, except in the case of
CMS experiments (see below), prucalopride (2.5 mg/kg/day), RS
67333 (1.5 mg/kg/day), citalopram (10 mg/kg/day), or the vehicle
were delivered through osmotic minipumps (Alza, Palo Alto, CA) in-
serted subcutaneously in the region of the back under short-duration
(%5 min) halothane anesthesia. The 5-HT depleter pCPA was admin-
istered once daily at the dose of 150 mg/kg, i.p., 72, 48, and 24 hr be-
fore the recordings. BrdU treatments consisted of two administrations
per day (50 mg/kg, i.p. each, 8 hr interval), starting from the day of mini-
pump insertion until day 2 postsurgery.uron 55, 712–725, September 6, 2007 ª2007 Elsevier Inc. 721
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Also, to lower the cost of these experiments (related to the high number
of animals used and to the frequency of injections), we chose to reduce
the dose of RS 67333 administered to 0.75 mg/kg/day.
Extracellular Recordings of DRN 5-HT Neurons
Recordings were performed using single-barreled glass micropi-
pettes, according to a procedure routinely performed in our laboratory
(Lucas and Debonnel, 2002).
Microiontophoresis and Extracellular Recordings
from Hippocampal CA3 Pyramidal Neurons
Recording and microiontophoresis were performed with five-barreled
glass micropipettes, according to a procedure routinely performed in
our laboratory (Lucas et al., 2005). The side barrels contained quisqua-
late (1.5 mM in 200 mM NaCl [pH 8]), WAY 100635 (15 mM in 200 mM
NaCl [pH 4]), and 2 M NaCl used for automatic current balancing.
Assessment of CREB and pCREB Immunoreactivities
Following decapitation (performed under halothane anesthesia), rat
brains were dissected on ice-cold artificial cerebrospinal fluid
(125 mM NaCl, 2.4 mM KCl, 0.83 mM MgCl2, 1.1 mM CaCl2, 0.5 mM
KH2PO4, 0.5 mM NaSO4, 27 mM NaHCO3, 10 mM glucose, 10 mM
HEPES [pH 7.4]). Isolated hippocampi (1–2 mg wet tissue/100 ml)
were homogenized in solubilization buffer containing 20 mM HEPES
(pH 7.9), 0.4 M NaCl, 20% (v/v) glycerol, 1% (v/v) Nonidet P-40,
5 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 1 mM phenylmethanesul-
fonyl fluoride, 1 mM okadaic acid, 5 mM dithiothreitol, 5 mg/ml leupep-
tin, 5 mg/ml soybean trypsin inhibitor, and 10 mg/ml benzamidine by
means of a dounce homogenator. Homogenates were then adjusted
to a concentration of 2 mg protein/ml and incubated on ice for
30 min, after which they were centrifuged for additional 30 min at
15,000 3 g. The supernatant was discarded, and SDS sample buffer
was added to the pellet for posterior immunoblot analysis. For detec-
tion of CREB activation, samples were sonicated and then boiled for
5 min before loading for SDS-PAGE that was performed as previously
described (Pin˜eyro et al., 2001) using a 4% stacking gel and 10% sep-
arating gel. Proteins resolved in SDS-PAGE were then transferred from
gels onto nitrocellulose (50 mA, 16 hr, Bio-Rad Mini-Trans Blot appa-
ratus) and pCREB detected by probing membranes with anti-pCREB
monoclonal antibody (1B6) from Cell Signaling Technology (1:1000).
Total CREB contents were determined after stripping by using
1:1000 dilution of anti-CREB antibody (Cell Signaling Technology).
Secondary antimouse (1:5000; Sigma) or antirabbit (1:40000; Amer-
sham) horseradish-conjugated antibodies and enhanced chemilumi-
nescence detection reagents (NEN Life Science Products) were used
to reveal blotted proteins. Relative intensities of the labeled bands
were analyzed by densitometric scanning using MCID (Imaging Re-
search Inc), and CREB-activation was expressed as the ratio between
pCREB and total CREB present in each sample. For each drug (citalo-
pram, prucalopride, and RS 67333), experiments were conducted in
parallel with three vehicle-treated animals (i.e., the ‘‘–’’ immunoblots
shown in Figure 5). Since values of the pCREB/CREB ratio did not dif-
fer statistically between these different controls, they were regrouped
to form the vehicle group of the histogram.
Measurement of Hippocampal Neurogenesis
Animals were deeply anesthetized by using an overdose of sodium
pentobarbital (75 mg/kg, i.p) and perfused transcardially with an initial
wash of heparinized 0.9% saline (50–100 ml, 4C), followed by 4%
paraformaldehyde in phosphate buffer (300 ml, 0.1 M [pH 7.4], 4C).
Brains were immersed for 48 hr in 30% phosphate-buffered sucrose
solution (pH 7.4) and then cut in the coronal plane at 50 mm on a sliding
freezing microtome. Free-floating sections were collected in phos-
phate-buffered saline (PBS, 0.1 M [pH 7.4]) as separate sets so that
each set contained every sixth serial section. Selected adjacent free-
floating sections were processed for double-labeling immunohisto-722 Neuron 55, 712–725, September 6, 2007 ª2007 Elsevier Incchemistry for BrdU (50-bromodeoxyuridine) and Nissl staining by using
minor modifications of a previously published method (Soriano and Del
Rio, 1991; Sadikot and Sasseville, 1997). Briefly, sections were incu-
bated in 0.5% sodium borohydride dissolved in PBS for 20 min and
rinsed twice in PBS. They were then incubated for 30 min in 1% triton
X-100 in PBS containing 0.03% hydrogen peroxide, followed by 1% di-
methlysulfoxide (DMSO) in PBS for 10 min. Sections were immersed in
2 N HCl in PBS for 60 min and then neutralized by rinsing in sodium bo-
rate buffer (0.1 M [pH 8.5]) for 5 min. After brief washes in PBS (three
times, 5 min each), they were preincubated in PBS containing 10% bo-
vine serum albumin (BSA) and 0.3% triton X-100 for 30 min, briefly
rinsed in PBS, and then incubated for 14–16 hr in PBS containing
anti-BrdU antibody (1:40, Becton Dickinson, San Jose, CA) and 2%
BSA (4C). After three brief rinses in PBS, sections were incubated in
PBS containing secondary antibody (biotinylated antimouse IgG,
1:200, Vector, Burlinghame, CA) and 2% BSA. Following three brief
rinses in PBS, sections were incubated for 1 hr in avidin-biotin complex
(ABC, 1%, in PBS, Vector). Next, sections were briefly rinsed three
times in PBS, and the immunohistochemical reaction product was
revealed by incubating for 7–10 min in a solution containing 0.37 mg
nickel ammonium sulfate, 25 mg 3.30-diaminobenzidine tetrahydro-
chloride (DAB), and 2 ml of hydrogen peroxide (30%) dissolved in
100 ml of Tris buffer (0.05 M [pH 7.6]). This nickel-enhanced DAB-
based chromogen yields a blue-black reaction product. Sections
were thoroughly rinsed in PBS and then mounted out of distilled water
on glass slides, air-dried, dehydrated in a 80% ethanol solution over-
night, then proceed with Cresyl Violet (CV) staining, cleared in Xylene
Substitute (Shandon, Pittsburgh, PA), and coverslipped with Permount
(Fisher, Fair Lawn, NJ).
Unbiased stereological estimates of the total number and volumetric
density of the BrdU-immunoreactive (IR) granule layer cells were
obtained by applying the optical fractionator (Luk and Sadikot, 2001)
with Stereo Investigator (Microbrightfield, Inc., Colchester, VT) using
an Olympus BX40 microscope and Optronix video camera. The rostral
and caudal limits of the left dorsal hippocampus were determined as
follows: equivalent to Bregma 2.30 mm (where the blades of the den-
tate gyrus become fully established) to 4.16 mm (when the hippo-
campus in coronal section contains both unfused dorsal and ventral
component) (Paxinos and Watson, 1986), and every 12 serial section
of 40 mm within this volume was examined. Typically, six coronal sec-
tions at 480 mm intervals were analyzed throughout the reference vol-
ume. Mean section thickness after immunohistochemical processing,
mounting, and coverslipping was 14 mm (tissue shrinkage effect), as
measured with a z axis microcator. For a given section, the outline of
the granule cell layer was traced at 103. Sampling of the dorsal hippo-
campus granule cell layer was performed by randomly translating
a grid with 753 75 mm squares onto the section of interest and apply-
ing an optical dissector consisting of a 60 3 60 3 10 mm brick. Each
section contained 69 to 133 sampling sites, depending on its surface
area. Sections were analyzed by using a 1003 lens (oil, numerical ap-
erture of 1.3, with matching condenser). Manual counts (at least one
section per animal) confirmed the accuracy of stereological results.
Forced Swim Test
We used the FST as previously described (Porsolt et al., 1977). Briefly,
rats experienced a pretest session followed 24 hr later by a test ses-
sion. For both the pretest and the test sessions, conducted under
low illumination (15 W), the animals were placed in a plastic cylindrical
tank (50 cm high by 20 cm in diameter) filled with water at 24C ± 1C,
with a depth of 40 cm, for which the hindlimbs could not reach the tank
floor. In all experiments, the pretest was carried out for 15 min and the
test for 5 min in the same tank, but only the last 4 min were analyzed.
Prucalopride (2.5 mg/kg, i.p.), RS 67333 (1.5 mg/kg, i.p.), and citalo-
pram (10 mg/kg, i.p.) were administered 30 min before the test session.
Following either pretest or test sessions, rats were dried with a towel
and kept warm for 30 min before being returned to their home cage.
A camera coupled with a computer recorded animal behavior online.
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ViewPoint, Lyon, France). This interface underscored online the sub-
traction of video frames. Immobility time in FST was derived from the
number of frames (every 40 ms) being below a predefined threshold
over FST duration. This threshold was preliminarily set up in order to
obtain about 95% of the corresponding frames classified as immobile
for a nonswimming rat in its water tank. The same threshold was kept
constant for naive as well as treated animals. A virtual rectangle was
also defined through the use of the interface, corresponding to the
space between the surface of water and the upper limit of the cylindri-
cal tank. Climbing behavior was counted as the time spent by the
animal in this area.
Measurements of locomotion were also performed in order to en-
sure that the decreased immobility or the increased active behaviors
in the FST were not secondary to a nonspecific increase in motor
activity produced by the treatments. Thirty minutes after drug admin-
istration, rats were placed in activity cages in which photoelectric cells
were inserted, allowing recordings of locomotor activity, i.e., quantifi-
cation of the total number of activity counts (photocell beam breaks)
during 10 min session.
Olfactory Bulbectomy and Assessment of Hyperlocomotion
Rats were anesthetized with pentobarbital (40 mg/kg, i.p.) and
mounted in a stereotaxic frame. The head was shaved, and a midline
sagittal incision was made, extending at least 1 mm to bregma. A
burr hole was drilled at points 7 mm anterior to bregma and 2.5 mm
either side of the midline at a point corresponding to the posterior mar-
gin of the orbit of the eye. After a localized electrical coagulation of the
dura and sagittal sinus, olfactory bulbs were removed by suction, and
the burr holes were filed with haemostatic sponges. Proviodine was
applied to the wound prior to closure using wound clips. In sham-
operated animals, the dura and the part of the sagittal sinus above
the bulbs were coagulated, but the bulbs were left intact. The animals
were given 11 days following surgery to recover prior to minipump in-
sertion and were handled daily to eliminate any aggressiveness that
may otherwise arise (Song and Leonard, 2005).
Minipumps (model 2ML2, specially designed for 2 week treatment)
were inserted as described above, and the open-field test was con-
ducted on days 3 and 14 after the implantation (i.e., 14 and 25 days
after bulbectomy, respectively). Each rat was placed singly into the
center of the open-field apparatus. This apparatus consisted of
a square wooden box (853 85 cm). Since the effects of OBX on loco-
motion are much more pronounced in conditions of high illumination
(Song and Leonard, 2005), experiments were conducted with a 75 W
bulb positioned 90 cm above the floor of the apparatus. Also, the inner
faces of the walls (70 cm high) were covered with aluminum foil. The
total distance covered by each animal over a 5 min period was mea-
sured by using the same interface as the one used for the FST (Video-
track, ViewPoint, Lyon, France). All experiments were performed
between 8:30 and 10:30 a.m.
Sucrose Consumption Test and Chronic Mild Stress Protocol
Animals were first trained to consume a palatable sucrose solution
(1.5%). The training lasted 5 weeks. In this period, the sucrose test
was made twice a week during the first 3 weeks and once a week
during the last 2 weeks. Animals were deprived of food and water
18 hr before the test, which consisted of 1 hr exposure to a bottle
with sucrose solution.
On the basis of sucrose intakes in the three final baseline tests, the
animals were then divided into two matched groups and placed in sep-
arate rooms. One group was exposed to an initial 2 weeks of chronic
mild stressors and the other was left undisturbed. The unchallenged
group was deprived of food and water for 14 hr before the sucrose
consumption test; otherwise, food and water were freely available.
The stress procedure was performed according to a procedure opti-
mized in our laboratory (Jayatissa et al., 2006). Briefly, the protocol
consisted of one period of intermittent illumination, stroboscopic light,Neugrouping, food, or water deprivation; two periods of soiled cage and no
stress; and three periods of 45 box tilting. During grouping, rats were
housed in pairs with different partners alternately being a resident or an
intruder. All the stressors lasted from 10 to 14 hr. After the initial
2 weeks of exposure to stress, the unchallenged and stress groups
were divided into three matched subgroups and subjected to chronic
RS 67333, citalopram, or vehicle administration. Stress was continued
during the entire period of treatment, the sucrose consumption test
being performed after 3 days of drug administration and then once
a week thereafter on days 10, 17, and 24.
Statistical Analysis
The comparison between the two slopes in Figure 2 was performed
by using GraphPad Prism software (version 3.03, GraphPad Software
Inc.). All other statistics were performed by using one-way ANOVAs,
followed by the Tukey’s test when multiple comparisons were
necessary.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/55/5/712/DC1/.
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